drugset / Trial / NCT05400811

Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis

NCT05400811 ↗

RandomizedParallel-groupTriple-blindTreatment

Summary

Prospective, randomized, placebo-controlled, multicenter of 3 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with mild to moderate asthma and rhinitis/rhinoconjunctivitis (intermittent or persistent) allergic to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae.

Timeline

Start
2022-12
Primary completion
2024-07
Completion
2025-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject MM09 Other / unclassified 3000 unknown Subcutaneous
Subject MM09 Other / unclassified 3000 unknown Other
Subject MM09 Other / unclassified 9000 unknown Other